{"id":49116,"date":"2018-09-19T01:00:00","date_gmt":"2018-09-26T01:55:25","guid":{"rendered":"http:\/\/www.05921.net\/index.php\/2018\/09\/26\/%e9%80%9f%e9%80%92-33-6%e4%b8%aa%e6%9c%88%ef%bc%81%e9%bb%91%e8%89%b2%e7%b4%a0%e7%98%a4%e9%9d%b6%e5%90%91%e7%bb%84%e5%90%88%e7%96%97%e6%b3%95%e5%85%ac%e5%b8%83%e6%9c%80%e6%96%b0os%e6%95%b0%e6%8d%ae\/"},"modified":"2018-09-26T09:55:27","modified_gmt":"2018-09-26T01:55:27","slug":"%e9%80%9f%e9%80%92-33-6%e4%b8%aa%e6%9c%88%ef%bc%81%e9%bb%91%e8%89%b2%e7%b4%a0%e7%98%a4%e9%9d%b6%e5%90%91%e7%bb%84%e5%90%88%e7%96%97%e6%b3%95%e5%85%ac%e5%b8%83%e6%9c%80%e6%96%b0os%e6%95%b0%e6%8d%ae","status":"publish","type":"post","link":"https:\/\/www.05921.net\/index.php\/49116\/","title":{"rendered":"\u901f\u9012 | 33.6\u4e2a\u6708\uff01\u9ed1\u8272\u7d20\u7624\u9776\u5411\u7ec4\u5408\u7597\u6cd5\u516c\u5e03\u6700\u65b0OS\u6570\u636e"},"content":{"rendered":"
\n

\u258e\u836f\u660e<\/span><\/strong>\u5eb7\u5fb7\/\u62a5\u9053<\/span><\/strong><\/strong><\/strong><\/strong><\/span><\/strong><\/strong><\/span><\/p>\n


<\/span><\/p>\n

\u8fd1\u65e5\uff0cArray\u516c\u5e03\u4e86\u5176BRAFTOVI\u00ae\uff08encorafenib\uff09\u548cMEKTOVI\u00ae\uff08binimetinib\uff09\u7ec4\u5408\u7597\u6cd5\uff0c\u5728\u6cbb\u7597\u643a\u5e26BRAFV600E\u6216BRAFV600K\u7a81\u53d8\uff0c\u4e0d\u53ef\u5207\u9664\u6216\u8f6c\u79fb\u6027\u9ed1\u8272\u7d20\u7624\u60a3\u8005\u7684COLUMBUS\u5173\u952e3\u671f\u8bd5\u9a8c\u4e2d\u53d6\u5f97\u7684\u603b\u751f\u5b58\u671f\uff08OS\uff09\u7ec6\u8282\u6570\u636e\uff0c\u8fd9\u4e00\u5177\u4f53\u7ed3\u679c\u53d1\u8868\u5728\u8fd1\u671f\u300aThe Lancet Oncology\u300b\u671f\u520a\u4e0a\u3002\u8be5\u7ec4\u5408\u7597\u6cd5\u5df2\u88abFDA<\/strong><\/span>\u6279\u51c6<\/strong><\/span><\/a>\u7528\u4e8e\u8fd9\u4e00\u9002\u5e94\u75c7\u3002<\/strong><\/span><\/p>\n

 <\/span><\/p>\n

\"\u901f\u9012<\/p>\n

<\/span>
<\/p>\n

\u8f6c\u79fb\u6027\u9ed1\u8272\u7d20\u7624\u662f\u4e25\u91cd\u548c\u5371\u53ca\u751f\u547d\u7684\u4e00\u79cd\u76ae\u80a4\u764c\u7c7b\u578b\uff0c\u5177\u6709\u975e\u5e38\u4f4e\u7684\u5b58\u6d3b\u7387\uff0c5\u5e74\u751f\u5b58\u7387\u4ec5\u4e3a20%\u3002\u5f53\u76ae\u80a4\u7ec6\u80de\u7684DNA\u53d7\u5230\u635f\u4f24\u800c\u6ca1\u6709\u5f97\u5230\u53ca\u65f6\u4fee\u590d\u65f6\uff0c\u4f1a\u5f15\u53d1\u4e00\u7cfb\u5217\u7a81\u53d8\u3002\u4e00\u4e9b\u7a81\u53d8\u53ef\u80fd\u5bfc\u81f4\u76ae\u80a4\u7ec6\u80de\u5f02\u5e38\u7e41\u6b96\u5e76\u5f62\u6210\u6076\u6027\u80bf\u7624\uff0c\u6bd4\u5982\u9ed1\u8272\u7d20\u7624\u3002\u5728\u8f6c\u79fb\u6027\u9ed1\u8272\u7d20\u7624\u4e2d\uff0c\u6700\u5e38\u89c1\u7684\u57fa\u56e0\u7a81\u53d8\u662fBRAF<\/em>\u7a81\u53d8\u3002\u5168\u4e16\u754c\u6bcf\u5e74\u8bca\u65ad\u51fa\u7ea6200,000\u4f8b\u9ed1\u8272\u7d20\u7624\u65b0\u75c5\u4f8b\uff0c\u5176\u4e2d\u7ea6\u4e00\u534a\u643a\u5e26BRAF<\/em>\u7a81\u53d8\uff0c\u8fd9\u662f\u8f6c\u79fb\u6027\u9ed1\u8272\u7d20\u7624\u7684\u5173\u952e\u6cbb\u7597\u9776\u70b9\u3002<\/span><\/p>\n

 <\/span><\/p>\n

\"\u901f\u9012<\/p>\n

<\/span>
<\/p>\n

Braftovi\u548cMektovi\u5206\u522b\u662fBRAF\u6fc0\u9176\u548cMEK\u6fc0\u9176\u7684\u53e3\u670d\u5c0f\u5206\u5b50\u6291\u5236\u5242\u3002\u4e24\u79cd\u836f\u7269\u5747\u9776\u5411MAPK\u4fe1\u53f7\u901a\u8def\uff08RAS-RAF-MEK-ERK\uff09\u4e2d\u7684\u5173\u952e\u9176\u3002\u8be5\u901a\u8def\u4e2d\u4e0d\u9002\u5f53\u7684\u86cb\u767d\u8d28\u6fc0\u6d3b\u5df2\u88ab\u8bc1\u660e\u5728\u8bb8\u591a\u764c\u75c7\u7c7b\u578b\u4e2d\u53d1\u751f\uff0c\u5305\u62ec\u9ed1\u8272\u7d20\u7624\uff0c\u7ed3\u76f4\u80a0\u764c\uff0c\u975e\u5c0f\u7ec6\u80de\u80ba\u764c\u7b49\u3002Braftovi\u4e0d\u9002\u7528\u4e8e\u6cbb\u7597\u91ce\u751f\u578bBRAF<\/em>\u7684\u9ed1\u8272\u7d20\u7624\u60a3\u8005\u3002<\/span><\/p>\n

 <\/span><\/p>\n

\"\u901f\u9012<\/p>\n

\u25b2Braftovi(encorafenib)\u548cMektovi(binimetinib)\u5747\u9776\u5411MAPK\u4fe1\u53f7\u901a\u8def\u4e2d\u7684\u5173\u952e\u9176\uff08\u53c2\u8003\u8d44\u6599[3]\uff09<\/span><\/strong><\/p>\n


<\/span><\/p>\n

COLUMBUS\u8bd5\u9a8c\uff08NCT01909453\uff09\u662f\u4e00\u9879\u4e24\u90e8\u5206\u3001\u5168\u7403\u3001\u968f\u673a\u3001\u5f00\u653e\u6807\u7b7e\u76843\u671f\u8bd5\u9a8c\uff0c\u65e8\u5728\u8bc4\u4f30Braftovi\u548cMektovi\u7ec4\u5408\u7597\u6cd5\uff0c\u4e0e<\/span>\u5176\u4ed6BRAF\u6291\u5236\u5242<\/span>\u6216Braftovi\u5355\u836f\u7597\u6cd5\u76f8\u6bd4\uff0c\u6cbb\u7597\u643a\u5e26BRAFV600<\/em>\u7a81\u53d8\u7684\u665a\u671f\u5c40\u90e8\uff0c\u4e0d\u53ef\u5207\u9664\u6216\u8f6c\u79fb\u6027\u9ed1\u8272\u7d20\u7624\u7684\u6709\u6548\u6027\u548c\u5b89\u5168\u6027\u3002\u672c\u6b21\u62a5\u9053\u7684\u662f\u5bf9\u5176\u6b21\u8981\u7ec8\u70b9\u603b\u751f\u5b58\u671f\uff08OS\uff09\u7684\u5206\u6790\u3002<\/span>\u7ec4\u5408\u7597\u6cd5\u7684\u4e2d\u4f4dOS\u4e3a33.6\u4e2a\u6708\uff0824.4-39.2\u4e2a\u6708\uff09\uff0c\u800c<\/span>\u5176\u4ed6BRAF\u6291\u5236\u5242<\/span>\u5355\u836f\u7597\u6cd5\u4e3a16.9\u4e2a\u6708\uff0814.0-24.5\u4e2a\u6708\uff09\u3002<\/span><\/strong>\u6b64\u5916\uff0c\u7ec4\u5408\u7597\u6cd5\u76842\u5e74\u603b\u751f\u5b58\u7387\u4e3a58%\u3002\u8bd5\u9a8c\u7684\u4e3b\u8981\u7ec8\u70b9\u662f\u6b64\u524d\u62a5\u9053\u8fc7\u7684\u4e2d\u4f4d\u65e0\u8fdb\u5c55\u751f\u5b58\u671f\uff08mPFS\uff09\u3002\u7ec4\u5408\u7597\u6cd5\u7684mPFS\u7ffb\u500d\uff0814.9\u4e2a\u6708\u6bd47.3\u4e2a\u6708\uff0cHR = 0.54\uff0c95\uff05CI 0.41-0.71\uff0cp <0.0001\uff09\u3002<\/span><\/p>\n

 <\/span><\/p>\n

\"\u901f\u9012<\/p>\n


<\/span><\/p>\n

\u54c8\u4f5b\u5927\u5b66\u533b\u5b66\u9662\u533b\u5b66\u6559\u6388\uff0c\u9ebb\u7701\u603b\u533b\u9662\u764c\u75c7\u4e2d\u5fc3Termeer\u9776\u5411\u6cbb\u7597\u4e2d\u5fc3\u4e3b\u4efbKeith T. Flaherty\u535a\u58eb\u8bf4\uff1a\u201c\u300aThe Lancet Oncology\u300b\u53d1\u8868\u7684COLUMBUS\u8bd5\u9a8c\u6700\u65b0\u7814\u7a76\u7ed3\u679c\uff0c\u51f8\u73b0\u4e86Braftovi\u548cMektovi\u7ec4\u5408\u7597\u6cd5\u4e3a\u643a\u5e26BRAF<\/em>\u7a81\u53d8\u7684\u9ed1\u8272\u7d20\u7624\u60a3\u8005\u6240\u5e26\u6765\u7684\u6cbb\u7597\u4ef7\u503c\u3002\u57fa\u4e8e\u8bd5\u9a8c\u89c2\u5bdf\u5230\u7684\u6709\u6548\u6027\u548c\u8010\u53d7\u6027\uff0c\u5bf9\u60a3\u6709\u8fd9\u79cd\u5371\u53ca\u751f\u547d\u7684\u9ed1\u8272\u7d20\u7624\u60a3\u8005\u6765\u8bf4\uff0c\u8fd9\u79cd\u9776\u5411\u6027\u7ec4\u5408\u7597\u6cd5\u662f\u4e00\u79cd\u91cd\u8981\u7684\u65b0\u6cbb\u7597\u9009\u62e9\u3002\u201d<\/span>
<\/p>\n


<\/p>\n

\u53c2\u8003\u8d44\u6599\uff1a<\/span><\/p>\n

[1]. Array BioPharma Announces Publication of BRAFTOVI\u00ae (<\/span>encorafenib<\/span>) + MEKTOVI\u00ae (<\/span>binimetinib<\/span>) Phase 3 Overall Survival Data in The Lancet Oncology. Retrieved September 14, 2018, from https:\/\/arraybiopharma.gcs-web.com\/news-releases\/news-release-details\/array-biopharma-announces-publication-braftovir-encorafenib<\/span><\/p>\n

[2]. Liszkay, et al., (2018). Overall survival in patients with BRAF-mutant melanoma receiving <\/span>encorafenib<\/span> plus <\/span>binimetinib<\/span> versus vemurafenib or <\/span>encorafenib<\/span> (COLUMBUS): a multicentre, open-label, <\/span>randomised<\/span>, phase 3 trial. The Lancet Oncology, https:\/\/doi.org\/10.1016\/S1470-2045(18)30497-2<\/span><\/p>\n

[3]. Van Loon K\uff0cet al., (2018). Emerging treatment options for BRAF-mutant colorectal cancer. Gastrointestinal Cancer: Targets and Therapy, https:\/\/doi.org\/10.2147\/GICTT.S125940<\/span><\/p>\n

[4]. \u9ed1\u8272\u7d20\u7624\u9776\u5411\u7597\u6cd5\u4eca\u65e5\u83b7\u6279\uff0c\u8fd1\u4e00\u534a\u60a3\u8005\u5c06\u83b7\u76ca. Retrieved September 14, 2018, from https:\/\/mp.weixin.qq.com\/s\/3WQAR7oV2QekLBHHuLax9w<\/span><\/p>\n


<\/p>\n

\u672c\u6587\u6765\u81ea\u836f\u660e\u5eb7\u5fb7\u5fae\u4fe1\u56e2\u961f\uff0c\u6b22\u8fce\u8f6c\u53d1\u5230\u670b\u53cb\u5708\uff0c\u8c22\u7edd\u8f6c\u8f7d\u5230\u5176\u4ed6\u5e73\u53f0\uff1b\u5982\u6709\u5f00\u8bbe\u767d\u540d\u5355\u9700\u6c42\uff0c\u8bf7\u5728\u6587\u7ae0\u5e95\u90e8\u7559\u8a00\uff1b\u5982\u6709\u5176\u4ed6\u5408\u4f5c\u9700\u6c42\uff0c\u8bf7\u8054\u7cfbwuxi_media@wuxiapptec.com<\/span>
<\/p>\n


<\/span><\/p>\n

\n<\/p><\/div>\n","protected":false},"excerpt":{"rendered":"

\u258e\u836f\u660e\u5eb7\u5fb7\/\u62a5\u9053 \u8fd1\u65e5\uff0cArray\u516c\u5e03\u4e86\u5176BRAFTOVI\u00ae\uff08encorafenib\uff09\u548cMEKTOVI\u00ae\uff08bi […]<\/p>\n","protected":false},"author":1,"featured_media":49117,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[2],"tags":[],"_links":{"self":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/49116"}],"collection":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/comments?post=49116"}],"version-history":[{"count":1,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/49116\/revisions"}],"predecessor-version":[{"id":49122,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/posts\/49116\/revisions\/49122"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media\/49117"}],"wp:attachment":[{"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/media?parent=49116"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/categories?post=49116"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.05921.net\/index.php\/wp-json\/wp\/v2\/tags?post=49116"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}